Table 4.
PP of WNV among humans and animals in Nigeria
| WNV marker | No. of studies | No. of subjects | PP (95% CI) | H | I2 | p-value |
|---|---|---|---|---|---|---|
| Humans | ||||||
| IgM seroprevalence | 7 | 1,879 | 7.1 (5.9, 8.3) | 292.3 | 92.4 | <0.0011 |
| IgG seroprevalence | 3 | 1,266 | 76.5 (74.0, 78.8) | 184.1 | 88.5 | <0.0011 |
| Neutralizing antibody prevalence | 6 | 2,164 | 14.3 (12.9, 15.8) | 548.6 | 98.5 | <0.0011 |
| Viral RNA prevalence | 4 | 1,473 | 1.9 (1.4, 2.9) | 33.3 | 25.6 | |
| Animals | ||||||
| IgM seroprevalence | 1 | 145 | 90.3 (84.3, 94.6) | NA | NA | NA |
| IgG seroprevalence | 1 | 376 | 3.5 (1.9, 5.8) | NA | NA | NA |
| Viral RNA prevalence | NA | NA | NA | NA | NA | NA |
| Neutralizing antibody prevalence | 3 | 620 | 20.0 (12.9, 21.4) | 25.8 | 48.5 | 0.072 |
PP, pooled prevalence; WNV, West Nile virus; CI, confidence interval; H, Cochrane Q, chi square for heterogeneity; Ig, immunoglobulin; NA, not applicable.
1
Significant heterogeneity (p<0.05).